These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 34326139)

  • 41. Cytochrome P450 3A4 and CYP3A5-Catalyzed Bioactivation of Lapatinib.
    Towles JK; Clark RN; Wahlin MD; Uttamsingh V; Rettie AE; Jackson KD
    Drug Metab Dispos; 2016 Oct; 44(10):1584-97. PubMed ID: 27450182
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Overcoming Time-Dependent Inhibition (TDI) of Cytochrome P450 3A4 (CYP3A4) Resulting from Bioactivation of a Fluoropyrimidine Moiety.
    Mandal M; Mitra K; Grotz D; Lin X; Palamanda J; Kumari P; Buevich A; Caldwell JP; Chen X; Cox K; Favreau L; Hyde L; Kennedy ME; Kuvelkar R; Liu X; Mazzola RD; Parker E; Rindgen D; Sherer E; Wang H; Zhu Z; Stamford AW; Cumming JN
    J Med Chem; 2018 Dec; 61(23):10700-10708. PubMed ID: 30388368
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Potential strategies for minimizing mechanism-based inhibition of cytochrome P450 3A4.
    Zhou SF
    Curr Pharm Des; 2008; 14(10):990-1000. PubMed ID: 18473851
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Metabolic activation of mifepristone [RU486; 17beta-hydroxy-11beta-(4-dimethylaminophenyl)-17alpha-(1-propynyl)-estra-4,9-dien-3-one] by mammalian cytochromes P450 and the mechanism-based inactivation of human CYP2B6.
    Lin HL; Zhang H; Hollenberg PF
    J Pharmacol Exp Ther; 2009 Apr; 329(1):26-37. PubMed ID: 19168709
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Analysis of Mechanism-Based Inhibition of CYP 3A4 by a Series of Fluoroquinolone Antibacterial Agents.
    Watanabe A; Takakusa H; Kimura T; Inoue S; Kusuhara H; Ando O
    Drug Metab Dispos; 2016 Oct; 44(10):1608-16. PubMed ID: 27469000
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Impact of the Hepatocyte-to-Plasma pH Gradient on the Prediction of Hepatic Clearance and Drug-Drug Interactions for CYP2C9 and CYP3A4 Substrates.
    Rougée LRA; Mohutsky MA; Bedwell DW; Ruterbories KJ; Hall SD
    Drug Metab Dispos; 2017 Sep; 45(9):1008-1018. PubMed ID: 28679672
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Unraveling a Combined Inactivation Mechanism of Cytochrome P450s by Genipin, the Major Reactive Aglycone Derived from
    Huang H; Zhao Y; Huang C; Lv N; Zhao J; Sun S; Guo C; Zhao D; Chen X; Zhang Y
    Chem Res Toxicol; 2023 Sep; 36(9):1483-1494. PubMed ID: 37622730
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Metabolism-dependent inhibition of CYP3A4 by lapatinib: evidence for formation of a metabolic intermediate complex with a nitroso/oxime metabolite formed via a nitrone intermediate.
    Barbara JE; Kazmi F; Parkinson A; Buckley DB
    Drug Metab Dispos; 2013 May; 41(5):1012-22. PubMed ID: 23404373
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The inactivation of cytochrome P450 3A5 by 17alpha-ethynylestradiol is cytochrome b5-dependent: metabolic activation of the ethynyl moiety leads to the formation of glutathione conjugates, a heme adduct, and covalent binding to the apoprotein.
    Lin HL; Hollenberg PF
    J Pharmacol Exp Ther; 2007 Apr; 321(1):276-87. PubMed ID: 17251390
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Retrorsine, but not monocrotaline, is a mechanism-based inactivator of P450 3A4.
    Dai J; Zhang F; Zheng J
    Chem Biol Interact; 2010 Jan; 183(1):49-56. PubMed ID: 19818743
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evidence for cytochrome P450 3A4-mediated metabolic activation of SCO-267.
    Li C; Li X; Fan A; He N; Wu D; Yu H; Wang K; Jiao W; Zhao X
    Biopharm Drug Dispos; 2024 Feb; 45(1):30-42. PubMed ID: 38236698
    [TBL] [Abstract][Full Text] [Related]  

  • 52. NADPH-dependent covalent binding of [3H]paroxetine to human liver microsomes and S-9 fractions: identification of an electrophilic quinone metabolite of paroxetine.
    Zhao SX; Dalvie DK; Kelly JM; Soglia JR; Frederick KS; Smith EB; Obach RS; Kalgutkar AS
    Chem Res Toxicol; 2007 Nov; 20(11):1649-57. PubMed ID: 17907785
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibition of cytochrome P450 enzymes and biochemical aspects of mechanism-based inactivation (MBI).
    Kamel A; Harriman S
    Drug Discov Today Technol; 2013; 10(1):e177-89. PubMed ID: 24050247
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs.
    McConn DJ; Lin YS; Allen K; Kunze KL; Thummel KE
    Drug Metab Dispos; 2004 Oct; 32(10):1083-91. PubMed ID: 15377640
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In Vitro Screening of Six Protein Kinase Inhibitors for Time-Dependent Inhibition of CYP2C8 and CYP3A4: Possible Implications with regard to Drug-Drug Interactions.
    Filppula AM; Mustonen TM; Backman JT
    Basic Clin Pharmacol Toxicol; 2018 Dec; 123(6):739-748. PubMed ID: 29956478
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effect of ritonavir on human CYP2B6 catalytic activity: heme modification contributes to the mechanism-based inactivation of CYP2B6 and CYP3A4 by ritonavir.
    Lin HL; D'Agostino J; Kenaan C; Calinski D; Hollenberg PF
    Drug Metab Dispos; 2013 Oct; 41(10):1813-24. PubMed ID: 23886699
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3A.
    Polasek TM; Sadagopal JS; Elliot DJ; Miners JO
    Eur J Clin Pharmacol; 2010 Mar; 66(3):275-83. PubMed ID: 20012430
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mechanism-based inactivation of CYP3A by HIV protease inhibitors.
    Ernest CS; Hall SD; Jones DR
    J Pharmacol Exp Ther; 2005 Feb; 312(2):583-91. PubMed ID: 15523003
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate.
    Lillibridge JH; Liang BH; Kerr BM; Webber S; Quart B; Shetty BV; Lee CA
    Drug Metab Dispos; 1998 Jul; 26(7):609-16. PubMed ID: 9660842
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions.
    Kalgutkar AS; Obach RS; Maurer TS
    Curr Drug Metab; 2007 Jun; 8(5):407-47. PubMed ID: 17584015
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.